Capstone posts preliminary July–August organic revenue growth of 7.6% and gross profit growth of 6.5%

• Capstone Therapeutics Corporation flagged continued momentum in early Q3 2026.
• It projected additional revenue growth without a proportionate rise in its cost base as it expands its product portfolio and geographic reach through its distribution infrastructure.
• The outlook follows preliminary July–August results showing organic revenue up 7.6% year over year to about $14.0 million.
• Organic gross profit was up 6.5% to $3.5 million for July–August.
• Year to date through August 31, organic revenue rose 4.6% to about $48.1 million.
• Year to date through August 31, organic gross profit increased 6.5% to $12.5 million.
• Organic gross profit outpaced revenue growth despite contraction in the broader building-products market.
• The company plans to scale distribution in the Pacific Northwest.
• It plans to broaden Carolina Stone into siding.
• It plans to continue rolling out products such as Eldorado Stone to drive growth through existing infrastructure.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Capstone Therapeutics Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001437749-26-031664), on October 01, 2026, and is solely responsible for the information contained therein.